Mead Johnson Upbeat On China Outlook After Series Of Setbacks
This article was originally published in The Tan Sheet
Executive Summary
The infant nutritionals firm has put a poorly timed price increase behind it and is optimistic about the effects of a Hong Kong limit on formula exports on China sales. Additionally, a recall of Danone baby nutrition products in Asia is expected to benefit Mead Johnson over the next 9 to 12 months.
You may also be interested in...
In Brief: NAD trims BPI claims, formula price-fixing in China, FDA warns Formulife and identifies spiked supplements, NBTY’s consumer redress
BPI discontinues claims at NAD’s behest; China levies fines for infant formula price-fixing; Public Citizen pans OTC Oxytrol; FDA advises ProNatural supplements cannot be topical; FDA warns Formulife on DMAA; FDA uncovers more spiked supplements; NBTY pays back consumers over omega-3 claims; Algean reminded about re-inspection fee.
In Brief
FDA warns topical pain relievers can cause burns; FDA issues another DMAA warning letter; Senators blast FDA’s lack of caffeine concern; Perrigo faces guaifenesin delays; Mead Johnson gets back on track in China.
Danone Enters Infant Formula Market With Numico Acquisition
Groupe Danone's $16.8 billion acquisition of Royal Numico expands the firm's healthy nutrition focus with entry into the infant formula market and a stronger position in clinical nutrition, the company says July 10